Enhanced in vivo Targeting of Radiolabelled Peptides with the Means of Enzyme Inhibitors
AssigneeBioSynthema Inc.
InventorsTheodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
Claims40
Compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
Compounds for use in combination with a diagnostic or therapeutic vector in the diagnosis or treatment of a disease, in particular cancer, that increase the uptake of said vector at the disease site(s) by inhibiting the activity of degrading enzymes.
A composition comprising a therapeutic or diagnostic compound that comprises a moiety conjugated peptide, preferably a peptide-ligand conjugate, and one or more compounds that inhibit the activity of a hydrolase, wherein the hydrolase is a peptidase or an esterase.
A method of treating and/or diagnosing a disease comprising co-administration of a therapeutic or diagnostic compound with one or more compounds that inhibit the activity of at least one hydrolase, wherein the therapeutic or diagnostic compound comprises a biodegradable peptide-ligand conjugate and the hydrolase is a peptidase or an esterase.
Dependencies are inferred from the claim text.